BSE Circulars (16607)
Bombay Stock Exchange circulars covering trading rules, listing requirements, compliance guidelines, market operations, and regulatory changes for market participants.
| Date | Circular | Tags | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED (Scrip Code: 544673) equity shares will be transferred from Trade for Trade segment (MT Group) … | |||||||||||||||
MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED (Scrip Code: 544673) equity shares will be transferred from Trade for Trade segment (MT Group) to Rolling segment (M Group) effective January 21, 2026.
| |||||||||||||||
Trading in equity shares of MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED (Scrip Code: 544673) will be transferred from Trade for Trade … | |||||||||||||||
Trading in equity shares of MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED (Scrip Code: 544673) will be transferred from Trade for Trade segment (MT Group) to Rolling segment (M Group) effective January 21, 2026.
| |||||||||||||||
MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED equity shares to be transferred from Trade for Trade segment (MT Group) to Rolling segment (M … | |||||||||||||||
MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED equity shares to be transferred from Trade for Trade segment (MT Group) to Rolling segment (M Group) effective January 21, 2026.
| |||||||||||||||
BSE revises price bands for 23 scrips ranging from 2% to 20%, effective January 8, 2026, impacting daily trading limits for affected … | |||||||||||||||
BSE revises price bands for 23 scrips ranging from 2% to 20%, effective January 8, 2026, impacting daily trading limits for affected securities.
| |||||||||||||||
NATCO Pharma provides clarification on ongoing litigation news, while Cipla addresses USFDA Form 483 inspectional observations at supply … | |||||||||||||||
NATCO Pharma provides clarification on ongoing litigation news, while Cipla addresses USFDA Form 483 inspectional observations at supply partner Pharmathen's Greece facility.
| |||||||||||||||
NATCO Pharma clarifies ongoing litigation with no current material impact, while Cipla addresses USFDA Form 483 observations at partner … | |||||||||||||||
NATCO Pharma clarifies ongoing litigation with no current material impact, while Cipla addresses USFDA Form 483 observations at partner facility Pharmathen manufacturing Lanreotide Injection.
| |||||||||||||||
Three companies provide clarifications to BSE regarding increased volume/price movements in their securities, stating no undisclosed … | |||||||||||||||
Three companies provide clarifications to BSE regarding increased volume/price movements in their securities, stating no undisclosed material information and attributing movements to market conditions.
| |||||||||||||||
Three companies provide clarifications to BSE regarding unusual volume movements in their securities, stating no material information was … | |||||||||||||||
Three companies provide clarifications to BSE regarding unusual volume movements in their securities, stating no material information was withheld and movements are market-driven.
| |||||||||||||||
Daily bulletin listing book closure dates, record dates, and corporate actions including dividends, redemptions, and bonus issues for … | |||||||||||||||
Daily bulletin listing book closure dates, record dates, and corporate actions including dividends, redemptions, and bonus issues for various securities.
| |||||||||||||||
Bulletin No. 192/2025-2026 containing book closure dates, record dates, and corporate action details for various securities including … | |||||||||||||||
Bulletin No. 192/2025-2026 containing book closure dates, record dates, and corporate action details for various securities including dividends, bonus issues, and debt redemptions.
| |||||||||||||||